iCAD plans to highlight its artificial intelligence (AI) software for digital breast tomosynthesis (DBT), ProFound AI, at the upcoming ECR 2019 in Vienna.
The software was cleared on 7 December 2018 by the U.S. Food and Drug Administration (FDA). It detects malignant soft-tissue densities and calcifications while offering radiologists scoring information that indicates the likelihood that a detection or case is malignant, the company said.
At the meeting, iCAD will also preview ProFound AI for 2D mammography, currently pending the CE Mark.
